Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies

Journal of Chemotherapy

Volumn 9, Issue 4, 1997, Pages 267-272

  Hazel, D L ^a   Graham, J ^a   Dickinson, J P ^a   Newland, A C ^a   Kelsey, S M ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Neutropenia; Piperacillin tazobactam; Tazocin

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; COLISTIN; COTRIMOXAZOLE; FLUCONAZOLE; GLYCOPEPTIDE; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTEREMIA; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYCOSIS; NEUTROPENIA; PYREXIA IDIOPATHICA; RASH; SUPERINFECTION;

EID: 0030844458     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1997.9.4.267     Document Type: Article

References (23)

1. Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161: 381-396.
2. Wade JC, Schimpff SC, Newman KA, Weirnik PH. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 1982; 97: 503-508.
3. Klastersky J. Concept of empiric therapy with antibiotic combinations. Am J Med 1986; 80, Suppl 5c: 2-12.
4. Barnes RA, Rodgers TR. An evaluation ot empirical antibiotic therapy in febrile neutropenic patients. Br J Haematol 1987; 66: 137-140.
5. Kelsey SM, Weinhardt B, Collins PW, Newland AC. Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients. Eur J Clin Microbiol Infect Dis 1992; 11: 509-514.
6. European Organisation for Research and Treatment of Cancer International Antimicrobial Therapy Co-operative Group and National Cancer Institute of Canada. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951-958.
7. Viscoli C, Moroni C, Boni L et al. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis 1991; 13: 397-404.
8. Ramphal R, Bolger M, Oblon DJ et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomised prospective study. Antimicrob Agents Chemother 1992; 36: 1062-1067.
9. Gold HS, Moellering JR. Antimicrobial drug resistance. N Engl J Med 1996; 335 (19): 1445-1453.
10. Montecalvo MA, Shay DK, Patel P et al. Bloodstream infections with vancomycin resistant enterococci. Arch Intern Med 1996; 156 (13): 1458-1462.
11. Gin AS, Zhanel GG. Vancomycin-resistant enterococci. Ann Pharmacother 1996; 30 (6): 615-624.
12. Pizzo PA, Hathorn JW, Hiemenz J et al. A randomised trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552-558.
13. De Pauw BE, Deresinski SC, Field R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 1994; 120: 834-841.
14. Cometta A, Calandra T, Gaya H et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for lever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108-1115.
15. Wexler HM, Molitoris E, Finegold SM. Effect of β-lactamase inhibitors on the activities of various β-lactam agents against anaerobic bacteria. Antimicrob Agents Chemother 1991, 35: 1219-1224.
16. Kelsey SM, Weinhardt B, Pocock CE, Shaw E, Newland AC. Piperacillin-tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with haematological malignancy. J Chemother 1992; 4 (5): 281-285.
17. Stefani S, Castiglia P, Maida A, Muresu E, Mezzatesta ME, Nicoletti G. Comparitive in-vitro activity of piperacillin and piperacillin plus tazobactam towards β-lactam agents against anaerobic bacteria. J Chemother 1990; 2: 295-299.
18. Cometta A, Zinner S, De Bock R et al. Piperacillintazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39 (2): 445-452.
19. Immunocompromised Host Society. The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990; 161: 397-401.
20. Holoszyc HM. An economical automated antibiotic disk-MIC testing system. Am Clin Lab 1996, 4: 15-17.
21. Del Favero A, Bucaneve G, Menichetti F. Empiric monotherapy in neutropenia: a realistic goal? Scand J Infect Dis 1995; (Suppl 96): 34-37.
22. Leyland MJ, Bayston KF, Cohen J et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992; 30: 843-854.
23. The Meropenem Study Group. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1992, 36: 185-200.